BioSpace News Archive

Takeda Pharmaceutical Company Limited announces that on May 28, the European Commission has released Takeda from the obligation to divest the pipeline compound SHP647 and certain associated rights, a commitment that was provided by Takeda to secure regulatory clearance of its acquisition of Shire plc.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced new data from analyses of two trials evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the pricing of an underwritten public offering of 16,000,000 shares of its common stock at a public offering price of $2.50 per share.

Iovance Biotherapeutics, Inc. (Nasdaq:IOVA) (“Iovance” or “Company”), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today announced the pricing of an underwritten public offering of 16,935,484 shares of its common stock at a public offering price of $31.00 per share

CARB-X announced today it is awarding Microbion Corporation of Bozeman, MT, USA, up to $6.1 million plus up to $5.4 million more if certain project milestones are met, to develop its anti-infective drug pravibismane for the treatment of cystic fibrosis (CF)-related pulmonary infections.

Themis, a company focused on vaccines and immune-modulation therapies for infectious diseases and cancer and MSD (trademark of Merck & Co., Inc., Kenilworth, N.J., USA, NYSE: MRK) today announced that the companies have entered into a definitive agreement under which MSD, through a subsidiary, will acquire privately-held Themis.

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $27.50 per share

National Health Foundation (NHF)

The Texas Cardiac Arrhythmia at St. David’s Healthcare wants to ensure that our testing and treatment of patients is of the highest quality, and the health and safety of our employees and those who come to us for care is our primary concern.

Ergotron, a global movement company that builds environments that help people thrive, announced the launch of its Thermal Imaging Cart with Onboard Power designed to quickly detect a temperature in spaces where groups of people gather.